Treatment Options for Cerebral AVMs and Dural AVFs

The second of a three-part series on diagnosing, treating, and researching management options for intracranial malformations.

By Lyahn K. Hwang, BS; Vivek A. Kumar, PhD; Ravi R. Vissapragada, MD; Karen Y. Lui, MD; Matthew R. Fusco, MD; Christopher S. Ogilvy, MD; and Ajith J. Thomas, MD
 

Intracranial vascular malformations, although uncommon, carry significant morbidity and mortality rates when symptomatic in patients. The standard of care in neurosurgical management and treatment of these pathologies is constantly being reviewed as underlying mechanisms are discovered. In our first article in the February 2015 issue of Endovascular Today, we discussed the pathology of cerebral arteriovenous malformations (AVMs) and dural arteriovenous fistulas (DAVFs). In this second part, we focus on various materials that are available for current treatment options for cerebrovascular lesions and the associated advantages and pitfalls.

TREATMENT OPTIONS FOR CEREBROVASCULAR LESIONS

The mainstay of treatment for cerebral AVMs and DAVFs is to reduce the risk of a catastrophic bleed. In order to evaluate the efficacy and feasibility of various types of therapy, postprocedure hemorrhage rates and long-term deficits need to be compared. Endovascular embolization (eg, vascular occlusion via the use of microcatheters, flexible stents, and detachable latex balloons) has been used in the treatment of intracranial AVMs as early as the 1970s. Although currently available endovascular techniques still hold many risks, preoperative embolization is thought to optimize surgical treatment of cerebral AVMs and DAVFs and possibly increase the efficacy of subsequent radiotherapy.1,2

Direct surgical treatment for AVMs is generally elective, unless conditions require emergent actions such as in the case of a large, life-threatening hemorrhage. Before treatment, it is critical to establish the AVM architecture through angiography. Intracranial lesions are typically resected using standard microneurosurgical techniques: first ligating arterial feeders, followed by excision of the lesion nidus, and finally the draining vein with postresection angiography. Published reports of surgical excision of cerebral AVMs suggest a high success rate (92% to 100%) for grade I patients. Surgery may be considered for higher-grade AVMs, but because of the high risk, it is typically used with an adjunct like embolization or radiosurgery.

SOLID EMBOLIC AGENTS

Embolization offers a minimally invasive treatment of vascular abnormalities by reducing AVM size, decreasing intraoperative blood loss, reducing the frequency and severity of normal perfusion pressure breakthrough, and in certain cases, facilitating surgical removal of hypervascularized tumors.2,3 Furthermore, the rapid improvement of microcatheter technology has allowed more control over embolization procedures. Cerebral AVM embolization previously included image-guided injection of permanent solid embolics, such as polyvinyl alcohol (PVA) particles, thereby blocking the flow and subsequent thrombosis of the vessel.4-6 PVA particles, although biocompatible, tend to clog microcatheters, yielding considerable hemorrhagic and ischemic complication rates and rarely lead to a permanent cure when used alone.6,7

In contrast to PVA particles, polyurethane microspheres loaded with the radiolucent material tantalum (for more facile visualization on angiography) do not obstruct catheters because its surface is modified by grafting methacrylic acid, which, when converted into its sodium salt, becomes hydrophilic. Although in vitro studies have shown that microspheres are nonhemolytic, application of polyurethane microspheres has been limited because of the cytotoxic effect of its diluent, dimethyl sulfoxide.8,9

Polyhydroxybutyrate (PHB) microspheres have also been developed for therapeutic embolization, which have shown no evidence of any inflammatory reaction or tissue toxicity directly due to the microspheres. However, there was distorted morphology of the embolic agent within blood vessels and fresh thrombus formation.10

The use of large (400 μm), calibrated microspheres (Embozene microspheres, CeloNova BioSciences, Inc.) in the embolization of meningiomas has been shown to minimize hemorrhagic complications.6 Furthermore, polypropylene sutures, surgical silk, and cyanoacrylate glues have been previously utilized for embolization procedures.11 Even though sutures are relatively inexpensive and readily available, they are difficult to control after injection via a catheter and are not radiopaque. Silk causes an inflammatory response, leading to thrombosis of the vessel. Risks associated with cyanoacrylate glues include premature hardening while in the catheter as well as permanent lodging of the catheter into the embolus.

Temporary embolic agents have some advantages over permanent materials in cases when healing is desired before recanalization, such as in traumatic injuries. In the past, naturally induced thrombosis in vitro was used to occlude vessels for days to a few weeks. Due to its short-lived embolization, autologous blood clots have been replaced by gelatin sponges.11 Gelfoam is an absorbable gelatin-compressed sponge that induces platelet aggregation and inflammation of the vessel wall.

In addition to longer thrombosis times than natural methods, gelatin sponges can also be administered in multiple ways, including forming a slurry, which is then loaded into a syringe filled with contrast. Bovine-derived collagen fiber preparations have been shown to effectively occlude at the arteriolar level for weeks to months. These fibers induce inflammatory reactions of the vessel wall in addition to mechanically obstructing the vessel lumen.11 Temporary embolic agents, however, have increased risks of rebleeding, leading to premature recanalization of blood vessels.

Although a variety of solid embolic agents exist, improvements can be made to produce materials that are more easily administered, biocompatible, and cost-effective. Human collagen microbeads have been shown to be an effective embolic agent in experimental in vivo conditions. These biocompatible spherical particles have smooth surfaces that may prove to be more effective for human cerebral AVMs, producing total occlusion of blood vessels with effortless injection ability through flow-directed microcatheters (unlike PVA particles).12

LIQUID EMBOLIC AGENTS

Liquid embolic agents, such as cyanoacrylate-based materials and ethanol, have been used as fast-forming barriers against blood flow into a variety of lesions with vascular components, such as hypervascularized tumors and AVMs.12,13 Factors such as polymerization time, injection rate, and blood flow influence the level of obstruction and whether embolization occurs proximal or distal to the site of injection.14 In the past, the fast-polymerizing adhesive n-butyl cyanoacrylate (n-BCA)—chemically similar to cyanoacrylate-based superglues—was a routinely used liquid chemoembolic agent. Advantages of n-BCA include deep intranidal penetration, high thrombogenicity, permanent occlusion, and easy delivery via small atraumatic microcatheters.2 Other nonadhesive embolic agents, such as coils and PVA particles, tend to result in recanalization over time, preventing treatment of large AVMs with multistaged embolization. Because n-BCA polymerization is a relatively quick and uncontrollable process, however, the introduction of the new liquid embolic agent, Onyx (Medtronic), a less-adhesive and slower-polymerizing material, has made significant improvements in eliminating small brain AVMs and reducing the size of larger AVMs for surgical or radiosurgical treatment.15,16

Onyx is an ethylene vinyl alcohol copolymer dissolved in dimethyl sulfoxide (DMSO) that is a biocompatible, precipitation- based system in which polymers precipitate out of solution upon contact with blood and has been shown to successfully treat aneurysms and tumors of the peripheral vascular system in conjunction with coils in selected cases.1,9,17 Because the microcatheter tip is not glued within the blood vessel, it is possible to inject large volumes in a highly controlled manner without filling the draining veins.11 When compared to patients who received only n-BCA treatment, patients treated with Onyx were less likely to experience permanent neurologic deficits related directly to the procedure.17 In contrast to n-BCA, Onyx allows the occlusion of several different vessel feeders from a singe pedicle, thereby reducing operative time and risk of subsequent catheterizations.7 Because Onyx is dissolved in DMSO, a potentially toxic solvent, injection must occur slowly and in stages, resulting in a relatively challenging delivery technique. If delivered too quickly, studies have shown that DMSO induces vessel necrosis, resulting in vasospasm.18,19 However, the negative side effects related to hypotension, arrhythmia, or thrombosis of the embolized blood vessel were minimal when administered appropriately.17 Furthermore, Onyx is available in various product formulations where the relative composition of ethylene vinyl alcohol, and thus viscosity, is altered. The different forms, such as Onyx 18, 34, and 500, have allowed more targeted therapy against different pathologies. For example, Onyx 34 has been used in the treatment of high-flow DAVF and, only if needed, injection was continued with Onyx 18.20 As a biomaterial that allows accurate control of the embolization process while avoiding unintentional occlusion of nearby vessels, Onyx is a promising embolic agent that has been used primarily for occluding cerebral AVMs, filling endoleaks, and more recently in a few clinical studies, for filling intracranial aneurysms.21-26

Although Onyx has become the common agent of choice in endovascular embolization, some studies have found issues with reflux surrounding the microcatheter and inadvertent venous penetration.27 Moreover, complications related to the use of Onyx include nerve injury, soft tissue necrosis, and local skin ulceration.28 Thus, while Onyx is an example of great advancement in the development of therapeutic embolization, discovery of these complications has led to diminished use.

In addition to cerebral AVM treatment, Onyx has also been used in the treatment of intracranial DAVF.29,30 Approximately 10% to 15% of all intracranial AVMs are DAVFs, which result from abnormal arteriovenous connections within the dura. Symptoms of DAVFs range from headaches and tinnitus to intracranial hemorrhage, but also have the chance to be completely asymptomatic.7

Management of DAVFs includes isolated endovascular, surgical, or radiosurgical repair or a combination of these procedures. Endovascular treatment is used against aggressive forms of DAVFs to eliminate the cortical venous drainage, thereby reducing the risk of intracranial hemorrhage. Treatment is considered complete when Onyx penetrates the draining vein of the DAVF. Before the advent of Onyx, endovascular management of DAVFs was limited to cyanoacrylate, ethyl alcohol, coils, and particles. Similar to AVM treatment, there was an increasing need for a nonadhesive liquid embolic agent in the endovascular treatment of intracranial DAVF. Transarterial administration of Onyx via microcatheterization has been shown to be a safe and highly effective embolic agent for DAVF treatment, reporting a low recurrence rate in the short-term postoperative follow-up and no significant morbidity or mortality.7,30

Although Onyx has multiple beneficial properties when compared to n-BCA, the latter confers many advantages in situations such as fistulous arteriovenous shunts, leptomeningeal collaterals, and catheter positions distant from the nidus.11 Interestingly, hyperosmolar mannitol has been shown to act as an effective liquid tumor embolization agent particularly in treating meningioma by dehydration of endothelial and tumor cells and thus promoting intravascular thrombosis.4 Studies have shown a low rate of permanent neurologic complications and a high degree of safety associated with the use of liquid embolic agents in the reduction of nidal volume in cerebral AVMs before surgical or radiosurgical procedures.31

CURRENT STANDARD OF CARE

When complete endovascular AVM occlusion cannot be accomplished, additional treatment options including surgery or radiation therapy are considered. Currently, Onyx is routinely chosen for embolization procedures due to its superior ability to fill a cerebral AVM nidus compared to other materials. In cases where Onyx cannot be administered safely, n-BCA may be utilized for cerebral AVM occlusion. Furthermore, in certain cases, such as when direct AVFs are present, the use of n-BCA is favored over Onyx due to its adhesive properties, thus limiting distal migration of the material in vivo. Of importance, intranidal catheter tip injection of Onyx carries a higher risk of vessel rupture when used in small vessels. If ruptures are not recognized during catheter manipulation, they can result in large hematomas that may only be noted on postprocedure CT scan. Staged embolization sessions are advised to reduce ischemic complications and microcatheter trapping.17

Other treatment modalities for the management of cerebral AVMs and DAVFs have proven valuable, such as stereotactic radiosurgery. This technique may prevent hemorrhage, reduce seizure rates, and relieve headaches by irradiating the AVM, causing progressive luminal obliteration. Through focused radiation, surrounding brain tissue damage can be minimized. Previous studies suggest that radiosurgery is a safe and effective AVM treatment with few reported complications.32 However, radiosurgery is most effective for small AVMs with volumes < 10 cm3 or maximum diameter < 3 cm.32-34 Similar to the previous treatment modalities, angiography is still the standard to confirm complete obliteration of the lesion. Although dependent on the size of the cerebral lesion, radiosurgical procedures can be considered in the treatment of cerebrovascular malformations thought to be at high risk from an endovascular or direct surgical perspective.

Collagen and collagen-like materials have had a major impact on biomedical engineering, surgery, and treatment of vascular lesions. Concerns with species homology, immunogenicity, and rejection have been largely disqualified with several instances of safe use in surgical practice.35-37 For example, collagen-coated platinum coils are a mainstay for embolization of saccular aneurysms (as previously described here).38 Specific to vascular malformations, collagen/gelatin (heat/enzyme-denatured collagen) has been fabricated into microspheres with demonstrated utility in a variety of pathologies including renal, mandibular, uterine, and maxillofacial embolization.39-44 Groups have also used collagen mixed with other embolic materials, such as PVA, for improved outcomes.45

CONCLUSION

In this second article of a three-part series, we hope to give the readership a view into current treatment options for cerebrovascular lesions while highlighting limitations of current clinical practices. Selection of endovascular embolization versus surgery or a combination must be reviewed on a case-by-case basis, relative risks and likelihood of acceptable occlusion. The final article in the series will summarize ongoing research and future directions for the development of novel therapeutics.

Lyahn K. Hwang, BS, is with University of Texas Southwestern Medical School in Dallas, Texas. She has disclosed that she has no financial interests related to this article.

Vivek A. Kumar, PhD, is with the Department of Chemistry, Rice University in Houston, Texas. He has disclosed that he has no financial interests related to this article. Dr. Kumar may be reached at vak1000@gmail.com.

Ravi R. Vissapragada, MD, is with Department of Surgery, Tufts Medical Center in Boston, Massachusetts. He has disclosed that he has no financial interests related to this article.

Karen Y. Lui, MD, is with the Division of Pediatrics, Baylor College of Medicine in Houston, Texas. She has disclosed that she has no financial interests related to this article.

Matthew R. Fusco, MD, is with the Division of Neurosurgery, Beth Israel Deaconess Medical Center, Harvard Medical School in Boston, Massachusetts. He has disclosed that he has no financial interests related to this article.

Christopher S. Ogilvy, MD, is with the Division of Neurosurgery, Beth Israel Deaconess Medical Center, Harvard Medical School in Boston, Massachusetts. He has disclosed that he has no financial interests related to this article.

Ajith J. Thomas, MD, is with the Division of Neurosurgery, Beth Israel Deaconess Medical Center, Harvard Medical School in Boston, Massachusetts. He has disclosed that he has no financial interests related to this article. Dr. Thomas may be reached at athomas6@bidmc.harvard.edu; (617) 632-9785.

  1. Riley CM, McLemore R, Preul MC, Vernon BL. Gelling process differences in reverse emulsion, in situ gelling polymeric materials for intracranial aneurysm embolization, formulated with injectable contrast agents. J Biomed Mater Res B Appl Biomater. 2011;96:47-56.
  2. DeMeritt JS, Pile-Spellman J, Mast H, Moohan N, et al. Outcome analysis of preoperative embolization with N-butyl cyanoacrylate in cerebral arteriovenous malformations. AJNR Am J Neuroradiol. 1995;16:1801-1807.
  3. American Society of Interventional and Therapeutic Neuroradiology. Head, neck, and brain tumor embolization. AJNR Am J Neuroradiol. 2001;22(8 suppl): S14-S15.
  4. Feng L, Kienitz BA, Matsumoto C, et al. Feasibility of using hyperosmolar mannitol as a liquid tumor embolization agent. AJNR Am J Neuroradiol. 2005;26: 1405-1412.
  5. Li H, Pan R, Wang H, et al. Clipping versus coiling for ruptured intracranial aneurysms: a systematic review and meta-analysis. Stroke. 2013;44:29-37.
  6. Sluzewski M, van Rooij WJ, Lohle PN, et al. Embolization of meningiomas: comparison of safety between calibrated microspheres and polyvinyl-alcohol particles as embolic agents. AJNR Am J Neuroradiol. 2013;34:727-729.
  7. Nogueira RG, Dabus G, Rabinov JD, et al. Preliminary experience with onyx embolization for the treatment of intracranial dural arteriovenous fistulas. AJNR Am J Neuroradiol. 2008;29:91-97.
  8. Thanoo BC, Sunny MC, Jayakrishnan A. Tantalum-loaded polyurethane microspheres for particulate embolization: preparation and properties. Biomaterials. 1991;12:525-528.
  9. Vanninen RL, Manninen I. Onyx, a new liquid embolic material for peripheral interventions: preliminary experience in aneurysm, pseudoaneurysm, and pulmonary arteriovenous malformation embolization. Cardiovasc Intervent Radiol. 2007;30:196-200.
  10. Kassab AC, Pişkin E, Bilgiç S, et al. Embolization with polyhydroxybutyrate (PHB) microspheres: in-vivo studies. J Bioact Compat Poly. 1999;14:291-303.
  11. Krysl J, Kumpe DA. Embolization agents: a review. Tech Vasc Interv Radiol. 2000;3:158-161.
  12. Turjman F, Massoud TF, Vinters HV, et al. Collagen microbeads: experimental evaluation of an embolic agent in the rete mirabile of the swine. AJNR Am J Neuroradiol. 1995;16:1031-1036.
  13. Zheng LZ, Fan XD, Zheng JW, Su LX. Ethanol embolization of auricular arteriovenous malformations: preliminary results of 17 cases. AJNR Am J Neuroradiol. 2009;30:1679-1684.
  14. Kunstlinger F, Brunelle F, Chaumont P, Doyon D. Vascular occlusive agents. AJR Am J Roentgenol. 1981;136:151-156.
  15. van Rooij WJ, Sluzewski M, Beute GN. Brain AVM embolization with Onyx. AJNR Am J Neuroradiol. 2007;28:172-177; discussion 178.
  16. Ayad M, Eskioglu E, Mericle RA. Onyx: a unique neuroembolic agent. Expert Rev Medical Devices. 2006;3:705-715.
  17. Mounayer C, Hammami N, Piotin M, et al. Nidal embolization of brain arteriovenous malformations using Onyx in 94 patients. AJNR Am J Neuroradiol. 2007;28:518-523.
  18. Brennecka CR, Preul MC, Bichard WD, Vernon BL. In vivo experimental aneurysm embolization in a swine model with a liquid-to-solid gelling polymer system: initial biocompatibility and delivery strategy analysis. World Neurosurg. 2012;78:469-480.
  19. Brennecka CR, Preul MC, Vernon BL. In vitro delivery, cytotoxicity, swelling, and degradation behavior of a liquid-to-solid gelling polymer system for cerebral aneurysm embolization. J Biomed Mater Res B Appl Biomater. 2012;100:1298-1309.
  20. Saraf R, Shrivastava M, Kumar N, Limaye U. Embolization of cranial dural arteriovenous fistulae with ONYX: Indications, techniques, and outcomes. Indian J Radiol Imaging. 2010;20:26-33.
  21. Guimaraes M, Wooster M. Onyx (Ethylene-vinyl Alcohol Copolymer) in Peripheral Applications. Semin Intervent Radiol. 2011;28:350-356.
  22. Numan F, Omeroglu A, Kara B, et al. Embolization of peripheral vascular malformations with ethylene vinyl alcohol copolymer (Onyx). J Vasc Interv Radiol. 2004;15:939-946.
  23. Nevala T, Biancari F, Manninen H, et al. Type II endoleak after endovascular repair of abdominal aortic aneurysm: effectiveness of embolization. Cardiovasc Intervent Radiol. 2010;33:278-284.
  24. Martin ML, Dolmatch BL, Fry PD, Machan LS. Treatment of type II endoleaks with Onyx. J Vasc Interv Radiol. 2001;12:629-632.
  25. Jadhav AP, Pryor JC, Nogueira RG. Onyx embolization for the endovascular treatment of infectious and traumatic aneurysms involving the cranial and cerebral vasculature. J Neurointerv Surg. 2013;5:562-565.
  26. Tevah J, Senf R, Cruz J, Fava M. Endovascular treatment of complex cerebral aneurysms with onyx hd-500® in 38 patients. J Neuroradiol. 2011;38:283-290.
  27. Chiu AH, Aw G, Wenderoth JD. Double-lumen arterial balloon catheter technique for Onyx embolization of dural arteriovenous fistulas: initial experience. J Neurointerv Surg. 2014;6:400-403.
  28. Richter GT, Friedman AB. Hemangiomas and vascular malformations: current theory and management. Int J Pediatr. 2012;2012:645-678.
  29. De Keukeleire K, Vanlangenhove P, Kalala Okito JP, et al. Transarterial embolization with ONYX for treatment of intracranial non-cavernous dural arteriovenous fistula with or without cortical venous reflux. J Neurointerv Surg. 2011;3:224-228.
  30. Cognard C, Januel AC, Silva NA Jr, Tall P. Endovascular treatment of intracranial dural arteriovenous fistulas with cortical venous drainage: new management using Onyx. AJNR Am J Neuroradiol. 2008;29:235-241.
  31. Jayaraman MV, Marcellus ML, Hamilton S, et al. Neurologic complications of arteriovenous malformation embolization using liquid embolic agents. AJNR Am J Neuroradiol. 2008;29:242-246.
  32. Ogilvy CS, Stieg PE, Awad I, et al; Stroke Council, American Stroke Association. Recommendations for the management of intracranial arteriovenous malformations: a statement for healthcare professionals from a special writing group of the Stroke Council, American Stroke Association. Circulation. 2001;103:2644-2657.
  33. Sun S, Chou HW, Chen JS, Chan CY. Treating thrombotic prosthetic arteriovenous access with crossballoon occlusive thrombolysis and angioplasty. Asian J Surg. 2012;35:88-92.
  34. Yashar P, Amar AP, Giannotta SL, et al. Cerebral arteriovenous malformations: issues of the interplay between stereotactic radiosurgery and endovascular surgical therapy. World Neurosurg. 2011;75:638-647.
  35. Yannas IV. Emerging rules for inducing organ regeneration. Biomaterials 2013;34:321-330.
  36. Yannas IV, Tzeranis DS, Harley BA, So PT. Biologically active collagen-based scaffolds: advances in processing and characterization. Philos Trans A Math Phys Eng Sci. 2010;368:2123-2139.
  37. Lynn AK, Yannas IV, Bonfield W. Antigenicity and immunogenicity of collagen. J Biomed Mater Res B Appl Biomater. 2004;71:343-354.
  38. Purdy PD, Batjer HH, Risser RC, Samson D. Arteriovenous malformations of the brain: choosing embolic materials to enhance safety and ease of excision. J Neurosurg. 1992;77:217-222.
  39. Murata S, Onozawa S, Nakazawa K, et al. Endovascular embolization strategy for renal arteriovenous malformations. Acta Radiol. 2014;55:71-77.
  40. Kademani D, Costello BJ, Ditty D, Quinn P. An alternative approach to maxillofacial arteriovenous malformations with transosseous direct puncture embolization. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2004;97:701-706.
  41. Ghai S, Rajan DK, Asch MR, et al. Efficacy of embolization in traumatic uterine vascular malformations. J Vasc Interv Radiol. 2003;14,:1401-1408.
  42. Fathi M, Manafi A, Ghenaati H, Mohebbi H. Large arteriovenous high-flow mandibular, malformation with exsanguinating dental socket haemorrhage: a case report. J Craniomaxillofac Surg. 1997;25:228-231.
  43. Widlus DM, Murray RR, White RI Jr, et al. Congenital arteriovenous malformations: tailored embolotherapy. Radiology. 1988;169:511-516.
  44. Stanley RJ, Cubillo E. Nonsurgical treatment of arteriovenous malformations of the trunk and limb by transcatheter arterial embolization. Radiology. 1975;115:609-612.
  45. Lylyk P, Vinuela F, Vinters HV, et al. Use of a new mixture for embolization of intracranial vascular malformations. preliminary experimental experience. Neuroradiology. 1990;32:304-310.
 

Contact Info

For advertising rates and opportunities, contact:
Craig McChesney
484-581-1816
cmcchesney@bmctoday.com

Stephen Hoerst
484-581-1817
shoerst@bmctoday.com

Charles Philip
484-581-1873
cphillip@bmctoday.com

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.